Testing ovarian cancer organoids for personalized drug sensitivity
Drug Screening of Patient-derived Organoids From Ovarian Cancer Culture to Personalized Therapy,an Exploratory Research
This study is testing if lab-grown samples of ovarian cancer from patients can help doctors find the best medications for their specific treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Chongqing University Cancer Hospital Academic / other |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT04768270 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the use of patient-derived ovarian cancer organoids to assess drug sensitivity and guide precision treatment. Tissue samples from patients undergoing primary cytoreductive surgery will be cultured to create organoids, which will then be validated using Next Generation Sequencing and immunohistochemistry. The sensitivity of these organoids to standard chemotherapy and targeted agents will be compared to the treatments received by patients in clinical practice, providing insights into personalized treatment options.
Who should consider this trial
Good fit: Ideal candidates include ovarian cancer patients aged 18 to 70 who are scheduled for primary cytoreductive surgery and meet specific health criteria.
Not a fit: Patients with severe infections, liver disease, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored treatment options for ovarian cancer patients.
How similar studies have performed: While the use of organoids in cancer treatment is an emerging field, similar studies have shown promise in guiding personalized therapies, making this approach both innovative and relevant.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ovarian cancer patients who will accept primary cytoreductive surgery, with histopathological type: low/high grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma. 2. ECOG score 0\~1,age 18\~70 years old 3. Expected survival over 6 months 4. The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial 5. CBC：Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L； 6. Serum ALT≤2×UL, AST≤2×ULN；Serum creatinine≤1.5×ULN； Exclusion Criteria: 1. Activity or uncontrol severe infection 2. Liver cirrhosis, Decompensated liver disease 3. History of immune deficiency, including HIV positive or suffering from congenital immunodeficiency disease 4. Chronic renal insufficiency or renal failure 5. Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated 6. Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure 7. During the treatment for complications, the drugs which lead to serious liver and/or kidney function impairment need to be used, such as tuberculosis
Where this trial is running
Chongqing, Chongqing
- Chongqing Cancer Hospital — Chongqing, Chongqing, China (Recruiting)
Study contacts
- Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
- Study coordinator: Dongling Zou, M.D.
- Email: cqzl_zdl@163.com
- Phone: +8613657690699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.